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Unsaturated fatty acid regulation of cytochrome P450 expression via
a CAR-dependent pathway
Robert D. FINN, Colin J. HENDERSON, Claire L. SCOTT and C. Roland WOLF1
Cancer Research UK Molecular Pharmacology Unit, Biomedical Research Centre, Level 5, Ninewells Hospital and Medical School, Dundee DD1 9SY, U.K.
The liver is responsible for key metabolic functions, including
control ofnormal homoeostasis inresponseto diet andxenobiotic
metabolism/detoxiﬁcation. We have shown previously that inac-
tivation of the hepatic cytochrome P450 system through condi-
tionaldeletionofPOR(P450oxidoreductase)induceshepaticste-
atosis,livergrowthandP450expression.Wehaveexploitedanew
conditional model of POR deletion to investigate the mechanism
underlying these changes. We demonstrate that P450 induction,
liver growth and hepatic triacylglycerol (triglyceride) homoeo-
stasis are intimately linked and provide evidence that the
observed phenotypes result from hepatic accumulation of unsatu-
rated fatty acids, which mediate these phenotypes by activation of
the nuclear receptor CAR (constitutive androstane receptor) and,
to a lesser degree, PXR (pregnane X receptor). To our knowledge
this is the ﬁrst direct evidence that P450s play a major role in
controlling unsaturated fatty acid homoeostasis via CAR. The
regulation of P450s involved in xenobiotic metabolism by this
mechanism has potentially signiﬁcant implications for individual
responses to drugs and environmental chemicals.
Key words: constitutive androstane receptor (CAR), cytochrome
P450, linoleic acid, P450 oxidoreductase (POR), pregnane X
receptor (PXR), steatosis.
INTRODUCTION
CytochromeP450enzymes(P450s)playamajorroleinthemeta-
bolism and disposition of chemicals and their activities are
critical in determining the efﬁcacy or side effects of drugs.
These enzymes also have additional functions in adrenal steroid
hormone biosynthesis and the hepatic synthesis of cholesterol
and its degradation to bile acids [1]. The P450s involved in
these different pathways are distinct and their regulation has
conventionally been considered to be by different mechanisms.
This is manifest in that many of the hepatic enzymes involved
in foreign compound metabolism are expressed constitutively at
low levels, but become highly induced on exogenous chemical
exposure, resulting in an increased rate of excretion of the
compound(s). Signiﬁcant advances have been made in our
understanding of this adaptive response through the identiﬁca-
tion of transcription factors, such as AhR (aryl hydrocarbon
receptor), PXR (pregnane X receptor) and CAR (constitutive an-
drostanereceptor),whichhavethecapacitytobinddrugsandexo-
genous chemicals, resulting in transcriptional activation of genes
that mediate their detoxiﬁcation [2–5]. Although distinct classes
of compounds bind to each receptor, owing to the diversity of
these compounds’ chemical structures, promiscuity exists in their
speciﬁcity, particularly in the case of PXR and CAR [6,7].
We,andthegroupofDing,havereportedamousemodelwhere
hepatic P450 activity has been reduced by >95% by the condi-
tional deletion of the Por (P450 oxidoreductase) gene [8,9]. This
was achieved by crossing mice carrying the Por gene ﬂanked
by loxP sites with mice expressing Cre recombinase under the
control of the rat albumin promoter. This resulted in the speciﬁc
hepatic deletion of POR neonatally with a concomitant reduc-
tion in P450 activity [8,9]. Although HRN (hepatic reductase-
null) mice developed normally and were fertile, there were a
number of intriguing phenotypic changes, including an enlarged
liver and hepatic steatosis. Also, there was a profound increase in
the expression of a range of P450s, with the most marked changes
being in the expression of CYP2B10 (CYP is cytochrome P450)
and CYP3A11 [10]. These enzymes, which are expressed at low
levels in untreated animals, are highly inducible by exogenous
chemicals such as barbiturates and synthetic glucocorticoids
[11,12].ThesedatashowthattheP450systemisakeyregulatorof
hepaticlipidhomoeostasisandlivergrowthandthatthismetabolic
homoeostasis can have a profound effect on the control of P450
gene expression and, as a consequence, on the metabolism/
deposition of drugs. The HRN mouse therefore provides a model
for investigating the endogenous factors involved in regulating
P450 genes and the role of the P450 system in controlling hepatic
steatosis and liver growth.
Studiesofthetemporaleventsthatleadtothehepaticphenotype
are,however,notpossibleintheHRNmicebecausethedeletionof
thePor geneoccursneonatally.Toovercomethis,wehavecreated
a model where the HRN genotype is regulated conditionally and
in an inducible manner. This was achieved by crossing Por-
ﬂoxed mice with mice where Cre recombinase is conditionally
regulated by the rat Cyp1a1 promoter. This promoter is activated
through the AhR, and administration of a single dose of 3MC
(3-methlycholanthrene) at 40 mg/kg results in a speciﬁc, time-
dependent, hepatic deletion of POR and a phenotype identical
with that observed in HRN mice [13].
In the present study, we have used the new model to study
the temporal biochemical changes that control lipid accumul-
ation and P450 overexpression. We provide evidence that dietary
unsaturated fatty acids play a key role in both lipid accumul-
ation and P450 induction. Also, using nuclear receptor/HRN
Abbreviations used: AhR, aryl hydrocarbon receptor; CAR, constitutive androstane receptor; Cpt1a, carnitine palmitoyltransferase 1a; CYP, cytochrome
P450; FAS, fatty acid synthase; HRN, hepatic reductase-null; i.p., intraperitoneal; 3MC, 3-methylcholanthrene; P450, cytochrome P450; PB, phenobarbital;
POR, P450 oxidoreductase; PPAR, peroxisome-proliferator-activated receptor; PUFA, polyunsaturated fatty acid; PXR, pregnane X receptor; TCPOBOP,
1,4-bis-[2-(3,5-dichloropyridyloxy)]benzene.
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double- and triple-knockout mice, we show that P450
overexpression occurs predominantly through the activation of
CAR.
EXPERIMENTAL
Reagents
AllchemicalswerepurchasedfromSigma–Aldrich,exceptwhere
indicated.
Production of transgenic mice
Por
lox/lox/Cre
Alb (HRN) and Por
lox/lox/Cre
CYP1A1 mice on a C57/BL6
genetic background were generated as described previously
[9,13]. Littermates with the Por
lox/lox genotype were used as
controls. PXR-null (Pxr
−/−) and CAR-null (Car
−/−)m i c eo n
a C57/BL6 genetic background were crossed on to the HRN
line to generate Pxr
−/−/Por
lox/loxCre
Alb (Pxr
−/−/HRN) and Car
−/−/
Por
lox/loxCre
Alb (Car
−/−/HRN)double-knockoutmicerespectively.
Pxr
−/−/HRN and Car
−/−/HRN were crossed to gener-
ate Car
−/−/Pxr
−/−/Por
lox/loxCre
Alb (Car
−/−/Pxr
−/−/HRN) triple-
knockout mice. Pxr
−/−/Por
lox/lox, Car
−/−/Por
lox/lox and Car
−/−/
Pxr
−/−/Por
lox/lox littermates were used as controls. Pxr
−/− and
Car
−/− mice were identiﬁed by PCR as described previously
[14,15].
All mice were maintained under standard animal house condi-
tions with a 12 h light/12 h dark cycle and free access to water
and RM1 (control) diet (Special Diets Services). All studies were
carried out on 12-week-old male mice, except where indicated,
in accordance with the Animal Scientiﬁc Procedures Act (1986)
and after local ethical review.
Drug treatments
3MC in corn oil was administered to Por
lox/lox/Cre
CYP1A1 and
Por
lox/lox mice by i.p. (intraperitoneal) injection at 40 mg/kg of
body weight, and animals were killed at the indicated times.
Dietary restrictions
Por
lox/lox/Cre
CYP1A1 andPor
lox/lox micewereweanedandmaintained
on a control diet until 8 weeks of age before being transferred
to either a fat-deﬁcient diet (Special Diets Services, 821459)
or a fatty-acid-supplemented fat-deﬁcient diet (Supplementary
TableS1athttp://www.BiochemJ.org/bj/417/bj4170043add.htm),
for an additional 6 weeks. As controls, both Por
lox/lox/Cre
CYP1A1
and Por
lox/lox mice were weaned and maintained on the control
diet for the duration of the experiment. All diets were isocaloric
and free from cholesterol. At 12 weeks of age, mice were
administered either a single i.p. dose of 3MC (40 mg/kg of body
weight) or corn oil, and killed 14 days later.
For linoleic acid treatment, Por
lox/lox/Cre
CYP1A1 mice were main-
tained on the fat-deﬁcient diet as described above. At 12 weeks of
age, mice were administered a single i.p. dose of 3MC (40 mg/kg
of body weight), followed by an oral dose of linoleic acid of
65 mg/dayfromday5after3MCadministrationuntilbeingkilled
9 days later.
Immunoblotting and biochemical analysis
Microsomalfractionswerepreparedbydifferentialcentrifugation
[12], and protein concentrations were determined using the Bio-
Rad Protein Assay Reagent. Western blot analysis was carried
out as described previously [16] using 5 μg of microsomal pro-
tein per lane and polyclonal antisera raised against human POR
[17], murine CYP7A1 [13] or rat P450s [16]. Puriﬁed human
POR, rat CYP4A1 and the following murine P450s, CYP2B10,
His6–CYP3A11 and His6–CYP7A1, were used as standards.
Immunoreactive proteins were detected using horseradish-
peroxidase-conjugated donkey anti-(rabbit IgG) as a secondary
antibody (Dako) and visualized by ECL® Plus (enhanced chemi-
luminescence (GE Healthcare). The relative protein content of
individual P450s in microsomal fractions was determined by
direct scanning of ECL® membranes with Bio-Rad Quantity One
densitometrysoftware.PORactivitywasdeterminedbyNADPH-
dependentreductionofcytochromecasdescribedpreviously[17].
RNA isolation and real-time quantitative PCR analysis
Total RNA was isolated from snap-frozen liver samples using
TRIzol® (Invitrogen). Genomic DNA was removed using RQ1
DNase (Promega), and RNA (600 ng) was reverse-transcribed
using random hexamers and Superscript II RNase H reverse
transcriptase polymerase (Invitrogen). Real-time quantitative
PCR analysis was carried out with gene-speciﬁc primers for
CYP2B10, CYP3A11 and CAR as described previously [10]
and CD36 (Mm01135198_m1), FAS (fatty acid synthase)
(Mm01253292_m1) and Cpt1a (carnitine palmitoyltransferase
1a) (Mm00550438_m1) were supplied by Applied Biosystems.
Reactions were carried out in triplicate and monitored by meas-
uring ﬂuorescence at 518 nm with excitation at 494 nm. mRNA
levels were quantiﬁed using the Prism 7700 associated software
and GAPDH (glyceraldehyde-3-phosphate dehydrogenase) as
an internal standard.
Blood chemistry
Blood was collected by cardiac puncture into heparinized tubes,
andplasmawasanalysedfornon-fastingtotalcholesterolandnon-
fasting triacylglycerols (triglycerides) using assay kits (Thermo
Trace) on a Cobas Fara II centrifugal analyser (Roche).
Histopathology
Tissue samples were snap-frozen in Cryo-M-Bed (Bright
Instrument Co.), cryo-sectioned (10 μm) and stained with Oil
Red O (lipid content) or haematoxylin and eosin (morphological
analysis).
Lipid isolation and analysis
A small piece of liver was homogenized in PBS containing 0.1%
Triton X-100, and hepatic triacylglycerol and cholesterol levels
were determined using assay kits on a Cobas Fara II centrifugal
analyser [18].
Detailed fatty acid analysis of the various diets was carried out
by Special Diet Services (Supplementary Tables S2 and S3 at
http://www.BiochemJ.org/bj/417/bj4170043add.htm).
Plasmid construction
The plasmids pCMX Gal4-hPXR-LBD and p4*4xGal4-UAS-
luciferase were a gift from Luisella Vignati (Department of
Pharmacokinetics, Dynamics and Metabolism, Gruppo Pﬁzer
Inc., Italy) [19] and the former was used as a source of
the pCMX Gal4 vector to facilitate the generation of further
reporterconstructs.ThemouseCARligand-bindingdomainfrom
amino acids 118–358 (mCAR-LBD) was ampliﬁed using 5
 -GC-
GGAATTCGGTACTAAAGCATCTTTGCAACTGAA-3
  and5
 -
GCGGATCCTCAACTGCAAATCTCCCCGAGC-3
  as forward
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and reverse primers respectively, incorporating 5
  EcoRI and
3
  BamHI sites to facilitate cloning. The resulting 738 bp PCR
product was cloned as an EcoRI/BamHI fragment into pCMX
Gal4-hPXR-LBD replacing the hPXR-LDB section and generat-
ing the vector pCMX Gal4-mCAR-LBD.
Cell culture, transient transfection and cell treatments
All cell culture media and supplements were supplied by
Invitrogen. HepG2 cells were cultured in DMEM (Dulbecco’s
modiﬁed Eagle’s medium) containing 10%(v/v) heat-inactivated
foetal bovine serum, 1× non-essential amino acids, 100 units/ml
penicillin, 100 μg/ml streptomycin and 2 mM L-glutamine at
37◦Ca n d5% CO2.
HepG2 cells were transiently transfected with pCMX Gal4-
mCAR-LBD/p4*4xGal4-UAS-luciferase using the method of
Vignati et al. [19], with the following modiﬁcations: FuGENE
TM
6 (Roche) was used instead of Lipofectamine
TM Plus (Invitrogen),
assays were carried out in serum-containing medium and 0.2 μg
of the plasmid pRL-TK was included to allow normalization of
luciferase reporter gene activity. Cells were treated with
0.25–0.5 μM TCPOBOP {1,4-bis-[2-(3,5-dichloropyridyloxy)]-
benzene} and 1 mM PB (phenobarbital) as positive controls and
DMSO as a further control. Linoleic acid, complexed to fatty-
acid-free BSA at a molar ratio of 2:1, was tested at various
concentrations ranging from 0 to 12.5 μM, with the addition
of 20 μM α-tocopheryl succinate to prevent lipid peroxid-
ation.LuciferasereporteractivitywasdeterminedusingtheDual-
Luciferase Reporter Assay System (Promega).
RESULTS
Temporal analysis of the phenotypic changes observed
in the HRN mice
Por
lox/lox/Cre
CYP1A1 mice, in the absence of a chemical inducer,
werephenotypicallynormalandindistinguishablefromwild-type
animals. Treatment with a single dose of 3MC (40 mg/kg) led to a
time-dependentcompletedeletionofthehepaticPORandthedev-
elopment of a phenotype that was identical with that of the
original HRN model [13]. We therefore used this model to study
the sequential development of the HRN phenotypic traits over a
28 day period following 3MC treatment.
At 6 days after 3MC administration a >85% reduction in the
expression of POR protein, determined both by immunoblotting
and cytochrome c activity, had occurred (Figures 1A and 1B, i),
increasing to approx. 96% by day 14. These data were con-
ﬁrmed by immunohistochemistry where staining was reduced in
allhepatocytesbyday3andundetectableonday14andremained
absent for at least 28 days (results not shown). Treatment with
3MC resulted in the anticipated induction of CYP1A1 as a
consequence of the activation of the AhR. By days 7–9, CYP1A1
levels,presumablyduetothemetabolismandeliminationof3MC,
were undetectable, indicating that the level of CYP1A1 was not
induced by the POR deletion (Figure 1A). The transient changes
observed in CYP1A1 expression imply that Cre recombinase
expression would follow the same pattern and suggest that
the deletion of POR is reversible. Cre recombinase is indeed
expressed transiently, similarly to CYP1A1; however, return
of POR is dependent on cell turnover, which, in the case of
hepatocytes, takes several weeks. In Por
lox/lox/Cre
CYP1A1 mice, no
return of POR was observed for 60 days after 3MC treatment
(results not shown). In contrast, very marked increases in the
expression of other P450s were detected (Figure 1A). CYP2B,
CYP2C, CYP3A and CYP7A1 levels increased profoundly as a
function of time and in association with the decrease in POR
expression. Particularly marked changes were obtained in P450s
identiﬁed as CYP2B10 (corresponding to the upper band and
CYP2B9tothelowerbandaccordingtotheﬁndingsofLi-Masters
and Morgan [20]) and CYP3A11. Interestingly, a stepwise
increase in the level of CYP2B proteins occurred between days 9
and 11, whereas the increase in CYP2C and CYP3A proteins ap-
peared to occur more gradually. An induction of CYP7A1
occurred on day 7 and continued to increase until day 21 (Fig-
ure 1A). CYP4A levels decreased from day 11 in both control
(Por
lox/lox) as well as HRN mice, after which time they remained
slightly higher in HRN mice (results not shown). No changes
were observed in the expression levels of CYP2D proteins in
any samples. In control Por
lox/lox animals, 3MC treatment had no
effect on any of the P450s measured other than on the induction
of CYP1A1 (results not shown).
Associated with the time-dependent reduction in POR were
changes in liver size and non-fasting plasma total cholesterol
and triacylglycerols levels (Figure 1B, ii, iii and iv). Signiﬁcant
consistent changes in liver/body weight ratio were observed
from day 11, suggesting that other phenotypic changes must
precede this effect (Figure 1B, ii). A signiﬁcant decrease in non-
fasting plasma triacylglycerol levels also occurred at this time
(Figure1B,iv).Areductioninnon-fastingtotalplasmacholesterol
levels was also observed which reduced steadily from day 3, in
parallel with POR reduction (Figure 1B, iii), indicating that the
reduction in triacylglycerols occurs independently of the changes
in cholesterol, but in parallel with liver enlargement.
Loss of POR also led to a profound increase in hepatic lipids
(Figure 1C). This accumulation occurred rapidly after 3MC
administration and paralleled the loss of POR. At early time
points,increasesinlipidappearedtobelocalizedtotheperivenous
region, the major site of POR and P450 expression, and not to the
periportal region [21,22]. At later time points, this zonal local-
ization was lost, leading to lipid accumulation throughout the
liver. Quantiﬁcation of hepatic lipid content demonstrated that
the hepatic steatosis was due to increases in hepatic triacylgly-
cerols by day 11 (Figure 2A). No signiﬁcant changes in hepatic
cholesterollevelswereobservedovertheentiretimecourseofthe
experiment (Figure 2B). The changes in hepatic triacylglycerol
content were closely correlated with changes in both liver/body
weight ratio and the reduction in plasma triacylglycerols
(Figures 2C and 2D). This suggests that the level of hepatic
triacylglycerols determines the circulating triacylglycerol levels
and that they are related to liver enlargement.
Changes in hepatic lipid homoeostasis mediate P450 induction
Hepatic deletion of POR led to a profound time-dependent induc-
tion of several P450s, including members of the CYP2B and
CYP3Afamilies.Thisappearedtooccuratboththeproteinandthe
mRNA level [9,10]. Changes in CYP2B10 expression were ﬁrst
seenonday3,withaverymarkedincreasebetweendays9and11
(Figure 1A). The increases in CYP2B10 protein and mRNA were
not correlated with the decrease in POR activity (Supplementary
Figure S1A, i and ii, at http://www.BiochemJ.org/bj/417/
bj4170043add.htm) and therefore did not appear to be due to
changes in the metabolism of an endogenous inducing agent.
However, CYP2B10 protein and mRNA levels were correlated
with each other, indicating that the induction of the Cyp2b10
gene occurs mainly at a transcriptional level (Supplementary Fig-
ure S1A, iii). In addition, Cyp2b10 mRNA levels were correlated
with hepatic triacylglycerol concentration (Supplementary Fig-
ure S1A, iv). Similar analysis for CYP3A11 indicated that the
increased protein expression occurred more rapidly than for
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Figure 1 Time course of the phenotypic changes in conditional HRN mice
Porlox/lox/CreCYP1A1 andPorlox/lox miceweretreatedwithasingledoseof3MC(40mg/kgofbodyweight)beforeplasmaandliversampleswerecollectedatthetimepointsshown.(A)PORandP450
proteinexpression.Samplesrepresentapoolofthreeanimalspertimepointand5μgofhepaticmicrosomalproteinperlane.PuriﬁedhumanPORandmurineP450swereusedasstandards.(B)(i)
Hepatic microsomalPORactivity. (ii) Liver/bodyweightratios. Black bars:Porlox/lox/CreCYP1A1. Greybars:Porlox/lox. (iii) Non-fasting plasma total cholesterol.(iv) Non-fasting plasma triacylglycerol
(triglyceride) levels. Results are means+ −S.E.M. for three animals per time point, and in (i), (iii) and (iv) are expressed as a percentage compared with Porlox/lox mice at the same time point.
∗P 0.05; ∗∗P 0.01; ∗∗∗P 0.001 compared with Porlox/lox mice. (C) Hepatic lipid content was visualized by Oil Red O staining of snap-frozen sections. Photomicrographs were taken at 10×
magniﬁcation, bright ﬁeld, and are representative of the results from at least three mice per group.
CYP2B10, steadily increasing from day 2, reaching a maximum
by day 21, but also did not directly correlate with changes in
POR activity (Figure S1B). Although Cyp3a11 mRNA levels
were increased in POR mice, this did not correlate with the level
of CYP3A11 protein, indicating a more complex mechanism of
regulation of this gene (Supplementary Figure S1B, iii), possibly
involvingbothtranscriptionalandpost-translationalmechanisms.
Unlike Cyp2b10, only a weak correlation between the increases
in Cyp3a11 mRNA levels and hepatic triacylglycerol levels
was observed (Supplementary Figure S1B, iv). Thus differences
observed in the induction kinetics of CYP2B10 and CYP3A11,
at both the protein and the mRNA level, suggests that the
mechanisms regulating their overexpression are, at least in part,
distinguishable.
To determine the contributions of lipid uptake, oxidation and
synthesis to the development of the fatty liver phenotype and the
inductionofP450s,changesintheexpressionlevelsofCD36,FAS
and Cpt1a were determined in 3MC-treated Por
lox/lox/Cre
CYP1A1
mice compared with Por
lox/lox mice (Supplementary Figure S2 at
http://www.BiochemJ.org/bj/417/bj4170043add.htm). No signi-
ﬁcant changes in the expression levels of these genes were
observed, except for in Cpt1a on day 28 which showed a minor,
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Figure 2 Hepatic lipid accumulation and its relationship with organ weight and plasma lipid levels in conditional HRN mice
Porlox/lox/CreCYP1A1 andPorlox/lox miceweretreatedwithasingledoseof3MC(40mg/kgofbodyweight),andkilledontheindicateddays.(A)Hepatictriacylglycerol(triglyceride)concentrations.(B)
Hepatic cholesterol concentrations. Correlation of hepatic triacylglycerol concentration with (C) liver/body weight ratio and (D) non-fasting plasma triacylglycerol levels. Results are means+ −S.E.M.
for three animals per time point. ∗P 0.05; ∗∗P 0.01 compared with lipid levels on day 1.
but signiﬁcant, increase and may possibly be an attempt to
reverse lipid accumulation by increasing β-oxidation. Increased
expression of CD36 was observed on days 21 and 28 in
Por
lox/lox/Cre
CYP1A1 mice, which may contribute to the increase
in hepatic lipid at these time points; however, no correlation
could be made before day 21. There was no correlation between
the expression levels of these genes and the increases in P450
expression. They therefore do not appear to contribute to the lipid
accumulation.
Dietary fatty acids mediate P450 induction in HRN mice
In view of the ﬁnding that changes in hepatic fatty acid
homoeostasis correlated with the increases in P450 expression,
detailed fatty acid analysis was carried out on livers from
HRN and Por
lox/lox (control) mice (Supplementary Tables S4
and S5 at http://www.BiochemJ.org/bj/417/bj4170043add.htm).
Changes in all fatty acid classes occurred; however, the
most signiﬁcant changes were in mono-unsaturated and
polyunsaturated fatty acids (Supplementary Table S5), with
C16:1,C 18:1 and C20:3 increasing 6.78-, 14.06- and 6.19-fold
respectively (Supplementary Table S4). These data are in close
agreement with the report of Weng et al. [23], who, for their
HRN model, reported additional fold changes of 7.3 and 14.9 for
C18:3 and C20:1 unsaturated fatty acids respectively. Together, these
ﬁndings suggest that the accumulated hepatic triacylglycerols
preferentially contain unsaturated fatty acid chains and that these
fatty acid classes may mediate the P450 induction.
In the light of this possibility, Por
lox/lox/Cre
CYP1A1 mice were
placed on a fat-deﬁcient diet for 4 weeks before 3MC administr-
ation. This treatment completely prevented the increases in
P450 protein and mRNA expression as a consequence of POR
deletion (Figure 3A). Maintenance of control Por
lox/lox mice on
a fat-deﬁcient diet caused slight reductions in the constitutive
expression of CYP7A and CYP2C protein, and did not affect the
levels of the other P450s (results not shown). In addition to
the changes in hepatic P450 expression, maintenance of Por
lox/lox/
Cre
CYP1A1 mice on a fat-deﬁcient diet prevented the accumulation
of lipid in the livers of these animals (Figure 3C), resulting in an
Oil Red O staining pattern that was indistinguishable from that
of Por
lox/lox mice on a control diet. Also no signiﬁcant changes in
total plasma cholesterol or triacylglycerol levels were measured
on deletion of POR in Por
lox/lox/Cre
CYP1A1 mice fed a fat-deﬁcient
diet (Supplementary Figure S3). These data indicate that hepatic
triacylglycerol accumulation in POR mice originates from the
diet and that as a consequence of the inactivation of the P450
system an inability to maintain hepatic lipid homoeostasis occurs
which triggers increased P450 expression (possibly in an attempt
to restore normal hepatic lipid levels). It is worth noting that the
fat-deﬁcientdietalsopreventedtheliverenlargementseenonPOR
deletion, thus providing a metabolic link to all three phenomena.
InordertoidentifythefattyacidsthatmediatedP450induction,
various fatty acids were added back to the fat-deﬁcient diet
as outlined in Supplementary Table S1. Por
lox/lox/Cre
CYP1A1 and
Por
lox/lox were maintained on the supplemented diets and analysed
14 daysafter3MCadministration.Indietscontainingunsaturated
fattyacids,thelossofP450geneexpressionobservedwiththefat-
deﬁcientdietwasreversed.Thiswasparticularlythecasefordiets
containing sunﬂower oil (which is composed of approx. 88%
unsaturatedfattyacids)(Figure3B,SupplementaryTableS2).The
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Figure 3 Development of phenotypic changes in conditional HRN mice on
restricted fatty acid diets
Porlox/lox/CreCYP1A1 mice were maintained on a control diet until 8weeks of age, and then
either placed on a fat-deﬁcient or fatty-acid-supplemented diet, or continued on the control
diet, for a further 6 weeks. At 12weeks of age, they were treated with a single dose of 3MC
(40mg/kg of body weight) and killed 14 days later. (A) POR and P450 expression levels in
Porlox/lox/CreCYP1A1 and Porlox/lox mice maintained on a control or fat-deﬁcient diet treated
with 3MC (+) or corn oil (CO) (−). (i) Protein expression determined by Western blotting.
HepaticCyp2b10 (ii)andCyp3a11(iii)mRNAlevelsexpressedasafoldchangecomparedwith
Porlox/lox mice. (B) POR and P450 expression levels in Porlox/lox/CreCYP1A1 mice maintained
on fatty-acid-supplemented diets and treated with 3MC. (i) Protein expression determined by
Westernblotting.HepaticCyp2b10 (ii)andCyp3a11(iii)mRNAlevelsexpressedasafoldchange
compared with Porlox/lox mice. (C) Hepatic lipid content determined by Oil Red O staining of
snap-frozen liver sections of Porlox/lox/CreCYP1A1 mice maintained on fatty-acid-supplemented
dietsandtreatedwith3MC.Photomicrographsweretakenat10×magniﬁcation,brightﬁeld,and
are representative of the results from at least three mice per group. For mRNA analysis in (A)
and(B),resultsaremeans+ −S.E.M.(n=3). ∗P 0.05; ∗∗P 0.01; ∗∗∗P 0.001compared
with Porlox/lox mice. std, standard. Black bars: Porlox/lox/CreCYP1A1; grey bars: Porlox/lox.I na l l
panels:SFA,saturatedfattyacids;MUFA,mono-unsaturatedfattyacids;PUFA,polyunsaturated
fatty acids; SunFl, 1% sunﬂower oil.
inclusionofsaturatedfattyacidsinthedietwasessentiallywithout
effect. None of the treatments had effects on POR or P450 gene
expression in the control Por
lox/lox animals, with the exception of
CYP4Awhichwasinducedbyallthreeunsaturatedfattyaciddiets
(results not shown). Analysis of Cyp2b10 and Cyp3a11 mRNA
levels conﬁrmed that the changes in protein expression were at
least in part a result of transcriptional activation, the highest
increases in mRNA being found in mice on the sunﬂower-oil-
supplemented diet (Figure 3B, ii and iii). Analysis of plasma lipid
levelsrevealedsomeminordecreasesinbothtotalcholesteroland
triacylglycerol levels between Por
lox/lox/Cre
CYP1A1 and Por
lox/lox for
alldietarytreatments;however,thesewereonlysigniﬁcantforthe
sunﬂower-oil-supplemented diet where a 1.5- (P=0.036) and
1.8- (P=0.013) fold decrease was observed respectively (Sup-
plementary Figures S3A and S3B at http://www.BiochemJ.org/
bj/417/bj4170043add.htm). Hepatic lipid accumulation was
observed for all diets, except for the fat-deﬁcient diet, indicating
that lipid accumulation alone is not sufﬁcient to cause P450
induction (Figure 3C). In addition, no signiﬁcant increases in
liver/body weight ratio were observed for the diets used, except
thatcontainingsunﬂoweroils(SupplementaryFigureS3C).These
data indicate that lipid accumulation alone was not the cause of
liverenlargement,butthatunsaturatedfattyacidshadthecapacity
to induce the effect. Comparison of the fatty acid composition
of the diets (Supplementary Tables S2 and S3), identiﬁed C18:2
(linoleic acid), an n−6 PUFA (polyunsaturated fatty acid), as a
candidate fatty acid mediator of both P450 induction and liver
growth as it was the only fatty acid present in the diets that cor-
related with the effects observed. This hypothesis suggests that
the addition of linoleic acid as the sole dietary fatty acid should
be sufﬁcient to induce P450 expression in Por
lox/lox/Cre
CYP1A1 mice
maintained on a fat-deﬁcient diet. This was indeed found to be
the case, with oral administration of linoleic acid (65 mg/day
for 9 days) to Por
lox/lox/Cre
CYP1A1 mice on a fat-deﬁcient diet,
resulting in induction of CYP2B10, CYP3A11 and CYP2C
proteins (Figure 4A). Analysis of Cyp2b10 and Cyp3a11 mRNA
levels showed this induction to occur at the transcription level
(Figure 4B). In addition, administration of linoleic acid was
found to promote hepatic lipid accumulation (Figure 4C). This
lipid accumulation was reduced compared with Por
lox/lox/Cre
CYP1A1
micemaintainedonacontroldietandappearedtobeconcentrated
aroundthebloodvessels,apatternsimilartothatobservedatearly
time points following 3MC administration (Figure 1C); however,
in this case, it is probably due to differences in the amount of fat
intake. These results therefore indicate that linoleic acid, an n−6
dietary essential fatty acid, is a key regulator of P450 expression
in HRN models and that members of the CYP2B, CYP3A and
CYP2C, in a normal physiological situation, are involved in its
metabolism.
Role of nuclear receptors in P450 induction in HRN mice
Nuclear receptors that have been shown to mediate the regulation
of many P450 genes in response to exogenous chemicals [24,25]
have also been shown to play an important role in controlling
liver growth [26,27]. Of particular interest with regards to this
study were CAR and PXR, which have been intimately linked
to the regulation of CYP2B and CYP3A proteins in response to
both exogenous and endogenous inducing agents [28–30], and
PXR has been linked to triacylglycerol homoeostasis [27]. In
order to investigate whether these nuclear receptors mediate the
P450 overexpression in the HRN mice, we crossed the HRN
animals with mice nulled at either the Car or Pxr locus alone
or in combination to generate Car
−/−/HRN, Pxr
−/−/HRN and
Pxr
−/−/Car
−/−/HRN genotypes.
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Figure 4 Induction of hepatic P450 expression in conditional HRN mice by linoleic acid
Porlox/lox/CreCYP1A1 mice were maintained on a control diet until 8weeks of age, and then placed on a fat-deﬁcient diet for a further 6 weeks. At 12weeks of age, they were treated with a
single dose of 3MC (40mg/kg of body weight) and 5days later administered linoleic acid (65mg/day) for 9 days before being killed. (A) POR and P450 expression levels were determined by
Western blotting. WT, wild-type; std, standard; Con, control; F.D., fat-deﬁcient diet. (B) Hepatic Cyp2b10 (black bars) and Cyp3a11 (grey bars) mRNA levels expressed as a fold change compared
with Porlox/lox/CreCYP1A1 mice maintained on a fat-deﬁcient diet. Results are means+ −S.E.M. (n=3). ∗P 0.05 compared with Porlox/lox/CreCYP1A1 mice maintained on a fat-deﬁcient diet.
(C) Hepatic lipid content determined by Oil Red O staining of snap-frozen liver sections. Photomicrographs were taken at 10× magniﬁcation, bright ﬁeld, and are representative of the results from at
least three mice per group.
Loss of PXR did not affect POR deletion or the induction of
P450 proteins observed in HRN mice (Figure 5A). In agreement
with previous ﬁndings, Pxr
−/− mice exhibited slight increases in
CYP3A11 protein [14], and also CYP2B and CYP2C proteins
(Figure 5A, i); Cyp3a11 mRNA was also elevated relative to
levels in control Por
lox/lox mice (Figure 5A, ii). Basal expression
of Cyp2b10 mRNA was also very slightly increased (Figure 5A,
ii),althoughthiswasnotreﬂectedindetectableproteinexpression
(Figure 5A, i). The deletion of PXR did not affect the increases in
both CYP2B10 and CYP3A11 protein in HRN animals; however,
a reduction in both Cyp2b10 and Cyp3a11 mRNA levels was
observed, but this was not signiﬁcant compared with HRN mice
(Figure 5A, ii). No changes in plasma and hepatic lipid levels
were observed in Pxr
−/−/HRN mice compared with HRN mice
(Supplementary Table S6 at http://www.BiochemJ.org/bj/417/
bj4170043add.htmandFigure5D);however,inPxr
−/− mice,non-
fasting plasma total cholesterol and triacylglycerol levels were
reduced, the former signiﬁcantly, in comparison with wild-type
mice (Supplementary Table S6).
In relation to HRN mice nulled for CAR, profound changes
in the HRN phenotype were observed. The elevated expression
of CYP2B, CYP7A and CYP2C was markedly attenuated; how-
ever,CYP3A11expressionappearedtobeunaffected(Figure5B).
Analysis of mRNA levels also showed that no induction of
Cyp2b10 mRNA occurred in Car
−/−/HRN mice, indicating that
the increase in the expression of this P450 observed in HRN
mice was a consequence of CAR activation (Figure 5B, ii).
Interestingly, deletion of CAR in both control and HRN mice
further increased Cyp3a11 mRNA levels (Figure 5B, ii). The
reduction in non-fasting plasma total cholesterol and triacyl-
glycerol levels observed in the HRN mice were, however, not
reversed on the Car
−/− background (Supplementary Table S6);
however, a signiﬁcant reduction in hepatic lipid content for
Car
−/−/HRN mice compared with HRN mice was observed
(Figure 5D). These data suggest that, in addition to mediating
P450 induction in HRN mice, CAR plays a role in hepatic lipid
accumulation.
Finally,owingtothecross-talkbetweenPXRandCAR[31],the
effect of deleting both receptors on the development of the HRN
phenotype was analysed. In Pxr
−/−/Car
−/−/HRN mice, consistent
with the Car
−/− mice, the expression of CYP2B and CYP2C
proteins was profoundly reduced, whereas, in contrast, CYP7A
expression levels were only slightly affected (Figure 5C). In mice
nulled at both the Car and Pxr gene loci, a marked decrease in
CYP3A11 protein was also observed (Figure 5C, i). The change
in CYP2B protein expression was also reﬂected in a reduction in
Cyp2b10 mRNA levels (Figure 5C, ii). A slight decrease
in Cyp3a11 mRNA was observed in Pxr
−/−/ Car
−/−/HRN mice,
although this was not signiﬁcantly different from that of HRN or
Pxr
−/−/Car
−/− mice (Figure 5C, ii). Deletion of both CAR and
PXRonanHRNbackgroundresultedinanincreaseinnon-fasting
plasma total cholesterol level that was not signiﬁcantly different
from control (Por
lox/lox) mice. Although an increase in plasma
triacylglycerols was also observed, this was not signiﬁcantly
different from the HRN value (Supplementary Table S6). Hepatic
lipid content was reduced in Pxr
−/−/Car
−/−/HRN mice compared
with HRN mice, similar to levels observed in Car
−/−/HRN mice,
but still elevated compared with controls (Figure 5D); however,
this reduction did result in a change in liver size (Supplementary
Table S6).
Direct activation of CAR by linoleic acid in HRN mice
In order to establish whether PUFAs could activate CAR directly,
we carried out transactivation assays using a Gal4-CAR-LBD
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Figure 5 Induction of hepatic P450 expression and other phenotypes in HRN mice on nuclear receptor-null backgrounds
(A) POR and P450 expression levels in Pxr−/−/HRN mice: (i) protein expression determined by Western blotting; and (ii) hepatic Cyp2b10 (black bars) and Cyp3a11 (grey bars) mRNA levels
expressedasafoldchangecomparedwithPorlox/lox mice.(B)PORandP450expressionlevelsinCar−/−/HRNmice:(i)proteinexpressiondeterminedbyWesternblotting;and(ii)hepaticCyp2b10
(black bars) and Cyp3a11 (grey bars) mRNA expressed as a fold change compared with Porlox/lox mice. (C) POR and P450 expression levels in Car−/−/Pxr−/−/HRN mice: (i) protein expression
determinedbyWesternblotting;and(ii)hepaticCyp2b10 (blackbars)andCyp3a11(greybars)mRNAexpressedasafoldchangecomparedwithPorlox/lox mice.(D)Hepaticlipidcontentdetermined
byOilRedOstainingofsnap-frozenliversections.Photomicrographsweretakenat10×magniﬁcation,brightﬁeld,andarerepresentativeoftheresultsfromatleastthreemicepergroup.FormRNA
analysis in (A), (B)a n d( C), results are means+ −S.E.M. (n=3). ∗P 0.05; ∗∗P 0.01; ∗∗∗P 0.001 compared with Porlox/lox mice. WT, wild-type.
reporter assay in HepG2 cells [32]. In these experiments,
both TCPOBOP and linoleic acid could activate CAR directly
(Figure 6). PB, which is known to activate CAR by an indirect
mechanism, was not active in this assay. In view of reports that
the fatty-acid-sensitive transcription factor, PPARα (peroxisome-
proliferator-activated receptor α) can effect CAR expression
[33,34] and that the effects in the POR mice may be indirect,
we measured Car mRNA expression in Por
lox/lox/Cre
CYP1A1 mice.
Expression levels of CAR were found to be unchanged (Supple-
mentary Figure S2D).
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Figure 6 Activation of CAR by linoleic acid
HepG2 cells were transfected with pCMX Gal4-mCAR-LBD and p4∗4xGal4-UAS4-luciferase as
outlined in the Experimental section. Transfected cells were subsequently treated with linoleic
acidataconcentrationrangingfrom0to12.5μM,andluciferaseactivitywasanalysed24 hlater.
Transfectedcellsweretreatedwith0.25–0.5 μMTCPOBOPor1mMPBaspositiveandnegative
controlsrespectively.Results aremeans+ −S.E.M. (n=6determinations)andareexpressedas
a fold change compared with cells treated with either DMSO in the case of TCPOBOP and PB or
the 0μM sample in the case of linoleic acid. ∗P 0.05; ∗∗∗P 0.001.
DISCUSSION
The liver is the major organ controlling metabolic homoeostasis
due to dietary change. It is also the major tissue responsible for
drug and dietary chemical detoxiﬁcation through the actions of
phase I and phase II drug metabolism in which the P450 system
plays a pivotal role. Although it has been known for some time
that alterations in diet and disease states such as diabetes affect
the P450 system, there has been little evidence that P450s can
play a direct role in metabolic control [35–37]. However, there is
agrowingbodyofevidence,asdemonstratedinthepresentpaper,
that these pathways are intimately linked. This has a wide range
of implications not only for how alterations in P450 function may
inﬂuence the pathogenesis of disease, but also for how diet and
disease states may inﬂuence the metabolism and disposition of
drugs and environmental agents; for example, obesity in rats has
been shown to reduce expression levels of CAR and impaired
CYP2B induction by PB [38].
Themetabolicdialoguebetweenthepathwaysofdetoxiﬁcation
and metabolic homoeostasis are manifest in the ﬁndings that,
when the P450 system is inactivated, profound changes in lipid
homoeostasis and liver size occur which are paralleled by the
marked induction of P450s associated with drug metabolism in
the absence of an exogenous inducing agent. We have demon-
strated that P450s from a range of gene families are induced and
thatthisinductionparallelstheaccumulationofhepatictriacylgly-
cerols. We have also shown that the regulation of different P450s
is, in part, distinguishable, as exempliﬁed by CYP2B10 and
CYP3A11. CYP2B10 induction is almost entirely controlled at
the transcriptional level and occurs at a time point when there is
a stepwise increase in triacylglycerol accumulation, whereas, in
the case of CYP3A11, there is only a poor correlation between
mRNAinductionandproteinlevels,indicatingthatbothtranscrip-
tional and post-translational mechanisms are involved. The
latter mechanism could possibly occur via phosphorylation or
ubiquitination [39–41]. This may also be the case for CYP2C
proteins. Evidence for distinct pathways of regulation is also
reﬂected in the ﬁnding that the overexpression of these proteins
is, at least in part, mediated by different transcription factors (see
below). We have also demonstrated that hepatic steatosis is not
sufﬁcient to induce the hepatic P450 expression, but this effect
is mediated by dietary unsaturated fatty acids such as linoleic
acid, which we have found is sufﬁcient on its own to reverse the
fat-deﬁcient phenotype.
P450s of the CYP2B family are the major enzymes induced
in the liver by barbiturate drugs such as PB [42] and have the
capacity to metabolize fatty acids such as arachidonic acid [43].
Interestingly, Fulco and co-workers demonstrated over 20 years
ago that a fatty acid mono-oxygenase involved in fatty acid oxid-
ationinBacillusmegateriumishighlyinduciblebyPB[44,45].In
fact, studies on this pathway have demonstrated that its induction
provides an adaptive response against unsaturated fatty acid
toxicity[46].WhethertheinductionofenzymessuchasCYP2B10
and CYP3A11 in mammals are part of a similar detoxiﬁcation
pathway against dietary unsaturated fatty acids which are not
producedendogenously,suchaslinoleicacid,remainstobedeter-
mined.Howeverthedatainthepresentstudydoraisethepossibil-
ity that, under certain circumstances, diets containing unsaturated
fatty acids may inﬂuence hepatic detoxiﬁcation systems.
Awiderangeoftranscriptionfactorshavenowbeendiscovered
which control fatty acid homoeostasis and liver growth, including
PPARα,CAR,PXR,LXR(liverXreceptor)andHNF4α (hepato-
cyte nuclear factor 4α) [26,27,47–49]. For example, it has been
demonstrated that PPARα mediates liver growth induced by
perturbations in fatty acid homoeostasis as a consequence of
peroxisome proliferation and that PXR plays a role in controll-
ing hepatic triacylglycerol homoeostasis [27,50,51]. It was
therefore intriguing that the majority of the phenotypes resulting
from inactivation of the hepatic P450 system and the downstream
effectsonfattyacidhomoeostasisweremediatedbythetranscrip-
tion factor CAR. It has been postulated for some time that CAR
functionisregulatedbybothendogenousandexogenousinducing
agents including metabolic control through AMPK (AMP-activ-
ated protein kinase) [52], interaction with the forkhead transcrip-
tion factor FoxO1 (forkhead box O1) [53] and activation during
fasting [54]. It has also been postulated that CAR function can be
modulated by the fatty-acid-sensitive transcription factor PPARα
[33,34]. However, this mechanism of CAR activation would not
appear to explain the hepatic phenotype, as no changes in CAR
expression were found and also linoleic acid activated CAR dir-
ectly. However, to our knowledge, the ﬁnding that CAR may play
a role in linking the control of hepatic lipid homoeostasis and
endogenous P450 expression has not been reported previously.
We provide additional evidence that, for one group of enzymes
in the Cyp3a gene family, PXR may also play a role in deﬁning
the response to unsaturated fatty acids. The ﬁnding that feeding
conditional HRN mice a fat-deﬁcient diet prevents the induction
of CYP3A11 suggests that fatty acids, as well as bile acids [14],
can inﬂuence PXR function.
A possible pathway linking P450 function to the ﬁndings
observedinthepresentstudyisshowninFigure7.Asdescribedin
this model, dietary unsaturated fatty acids enter the liver via fatty
acid transporters, where, in wild-type mice, they are oxidized for
energy purposes or detoxiﬁed by P450s. Inactivation of the P450
system as a result of Por deletion leads to hepatic accumulation
of unsaturated fatty acids initially via increase import due to the
induction of lipid transporters such as CD36 [23] and a reduction
of plasma lipid levels. Hepatic lipid accumulation triggers the
activation of the nuclear receptor CAR (and possibly PXR),
leading to P450 induction and liver growth through the activation
of other downstream growth/transcription factors [26,27]. The
overexpression of P450s is aimed at re-establishing hepatic
lipid homoeostasis and the prevention of toxicity via increased
metabolism of unsaturated fatty acids. Inactivation of POR
preventsthisincreasedmetabolismandultimatelyleadstohepatic
steatosis, which establishes a cyclical process that promotes fur-
ther hepatic lipid accumulation and growth. The ability to control
the hepatic deletion of POR conditionally using the CYP1A1–
Cre system has allowed us to provide evidence in support of
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Figure 7 Schematic representation of the phenotypic changes that occur in HRN mouse models
Dietary unsaturated fatty acids enter the liver via fatty acid transporters where they are oxidized for energy purposes or detoxiﬁed by P450s. Inactivation of the P450 system as a result of Por deletion
leads to hepatic accumulation of unsaturated fatty acids and a reduction of plasma lipid levels. Hepatic lipid accumulation triggers the activation of the nuclear receptor CAR (and possibly PXR),
leadingtoP450inductionandlivergrowth.TheoverexpressionofP450sisaimedatre-establishinghepaticlipidhomoeostasisandthepreventionoftoxicityviaincreasedmetabolismofunsaturated
fatty acids. Inactivation of POR prevents this increased metabolism and ultimately leads to hepatic steatosis. The development of steatosis establishes a cyclical process that potentiates hepatic lipid
accumulation and growth. The adverse effect of P450 induction is altered drug metabolism and environmental chemical detoxiﬁcation, but, in addition, the increased production of oxidized lipids
could result in development of oxidative stress.
this pathway. Activation of Cre through the administration of
3MC resulted in the rapid deletion of POR, in that over 85%
of hepatocytes did not express the protein after 6 days. Although
accumulation of lipid was already occurring at this time point,
there appears to be a threshold at which point the CAR pathway
becomesactivated.Thishypothesisissupportedbytheﬁndingthat
itwasonlyafter9–11 daysthatamarkedchangeintriacylglycerol
accumulation occurred which was linked directly to changes in
plasma lipids, liver growth and P450 induction. Loss of P450
activity itself was not responsible for its auto-induction (although
the corresponding accumulation of a metabolite produced, e.g.
a bile acid precursor, which binds to CYP3A11 could explain
the stabilization of this protein). Whether the inactivation of the
P450 system causes the triacylglycerol accumulation and liver
growth and whether their induction is to attenuate the phenotypic
changesproducedremainsuncertain;however,itisquiteclearthat
the accumulation of hepatic triacylglycerols activates CAR. The
demonstrationofcross-talkbetweendrugsandlipidsonCARim-
plies that there will be drug–lipid interactions associated with ef-
fectsonthisreceptorandevidenceforthisisprovidedbythework
of Li et al. [55], who showed that PUFAs could inﬂuence the
induction of P450 genes by PB. Why the HRN phenotype results
in the reduction in circulating triacylglycerols and cholesterol
remains to be established. It is interesting to note, however, that
the cholesterol 7α-hydroxylase enzyme (CYP7A1) involved in
bile acid homoeostasis also appears to be affected by unsaturated
fattyacidlevelsinaCAR-dependentmannerandpossiblyaPXR-
dependent manner, as suggested by the opposing effects on this
protein’s expression observed in Car
−/− and Pxr
−/−/Car
−/−/HRN
mice. The effect observed here on this enzyme’s expression is
intriguing as a previous report suggested that CAR activation
represses CYP7A1 expression [56]. The contrasting results may
be a consequence of the fact that fasted, as opposed to non-fasted,
animals were used in the study of Miao et al. [56]. Despite this,
these data suggest the existence of a new pathway for the dietary
regulation of CYP7A1 by unsaturated fatty acids.
In summary, we have used a novel conditional HRN model to
investigate the sequential development of the phenotypic changes
observed in mice on deletion of POR. POR deletion and the
associatedinactivationofhepaticP450functionleadstoaccumul-
ation of dietary fatty acids in the liver, in the form of triacyl-
glycerols of unsaturated fatty acids, leading to organ enlarge-
ment and increased P450 expression, in the case of CYP2B,
CYP2C and CYP7A1 via a CAR-dependent signalling pathway.
The molecular mechanism underlying CYP3A11 expression
appears to involve CAR, PXR and protein stabilization. Induction
oftheP450systemappearstobemediatedbytheaccumulationof
PUFAs, such as linoleic acid (C18:2,n−6) and suggests that this may
be part of an adaptive response to prevent the deleterious effects
of PUFA accumulation. The ﬁnding that the major P450s that are
inducible by exogenous chemicals are also regulated by changes
in fatty acid homoeostasis has potentially signiﬁcant implications
for the variability observed in drug responses in humans.
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Unsaturated fatty acid regulation of cytochrome P450 expression via a
CAR-dependent pathway
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EXPERIMENTAL
Lipid isolation and analysis
For detailed fatty acid analysis, livers from 12-week-old HRN
male mice were collected and lipid-extracted using a modiﬁed
version of the Folch method [1]. Brieﬂy, internal standard
triheptadecanoin was added to a weighed amount of wet mouse
liver and homogenized in chloroform/methanol (1:1, v/v). An
equal volume of saline was added, before being centrifuged, and
the organic layer was removed and dried under vacuum. The lipid
residuewastransesteriﬁedwith5%sulfuricacidinmethanol,and
themethylfattyacidswereextractedintoheptane.Separationwas
achieved by injection into an SGE BPX-70 capillary column in a
Unicamseries610gaschromatographwithtemperatureprogram-
ming. Data were collected with a Phillips PU6030 data capture
unit and processed using Unicam 4880 data handling software.
Fatty acid quantiﬁcation was by internal standardization with
sample concentrations calculated by comparing the sample fatty
acid/internal standard ratio against the fatty acid/internal standard
ratioofknownamountsofacommercialfattyacidstandardwithin
a known linear range of standard ratios. The same amount of
internal standard was added to both standard and sample.
Table S1 Fatty acids added to a fat-deﬁcient base diet
Values are expressed as the amount of fatty acid (in g) in 100g of food (w/w). The control
diet is included for comparison purposes. A fourth supplemented diet was used consisting of
a fat-deﬁcient base diet plus 1% sunﬂower oil. None of the diets contained cholesterol and
were all isocaloric. MUFA, mono-unsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA,
saturated fatty acid. NA, not applicable.
Fatty acid Control diet SFA diet MUFA diet PUFA diet
Lauric acid (C12:0) 0.02 0.02 NA NA
Myristic acid (C14:0) 0.14 0.14 NA NA
Palmitic acid (C16:0) 0.31 0.31 NA NA
Stearic acid (C18:0) 0.04 0.04 NA NA
Myristoleic acid (C14:1) 0.02 NA 0.02 NA
Palmitoleic acid (C16:1) 0.09 NA 0.09 NA
Oleic acid (C18:1) 0.77 NA 0.77 NA
Linoleic acid (C18:2,n−6) 0.69 NA NA 0.69
Linolenic acid (C18:3,n−3) 0.06 NA NA 0.06
Arachidonic acid (C20:4,n−6) 0.13 NA NA 0.13
Total fatty acids 2.27 0.51 0.88 0.88
Table S2 Fatty acid analysis of the diets used
Values are expressed as a percentage of total fatty acid content on a fresh weight basis. MUFA,
mono-unsaturated fatty acid; PUFA, polyunsaturated fatty acid; SFA, saturated fatty acid.
Control Sunﬂower
Fatty acid group diet SFA diet MUFA diet PUFA diet oil diet
Saturated fatty acids 19.3 96.5–97.9 1.9–3.4 29.2–30.2 12.4–13.3
Mono-unsaturated fatty acids 18.3 1.7–2.1 95.1–95.5 11.8 24.8–25.1
Polyunsaturated fatty acids 62.2 1.0–2.0 2.1–3.2 16.0–16.3 61.9–62.9
Other unknown fatty acids 0.2 0.9 1.29 41.7–43.0 0.9
Table S3 Fatty acid analysis of the diets used
Values are expressed on a w/w basis in the diet. MUFA, mono-unsaturated fatty acid; PUFA,
polyunsaturated fatty acid; SFA, saturated fatty acid.
Sunﬂower
Fatty acid group Control diet SFA diet MUFA diet PUFA diet oil diet
Lauric acid (C12:0) <0.003 0.016 0.001 0.004 0.001
Myristic acid (C14:0) 0.006 0.099 0.002 0.012 0.003
Myristoleic acid (C14:1,n−5) <0.003 <0.001 0.012 0.003 <0.001
Pentadecanoic acid (C15:0) 0.003 0.001 0.001 0.1 0.001
Palmitic acid (C16:0) 0.48 0.32 0.009 0.05 0.067
Palmitoleic acid (C16:1,n−7)0 . 0 1 <0.001 0.07 0.003 0.001
Stearic acid (C18:0) 0.05 0.05 0.001 0.017 0.039
Oleic acid (C18:1,n−9) 0.47 0.007 0.74 0.039 0.237
Vaccenic acid (C18:1,n−7)0 . 0 3 <0.001 0.01 0.002 0.006
Linoleic acid (C18:2,n−6) 1.63 0.002 0.017 0.106 0.616
Linolenic acid (C18:3,n−3)0 . 1 7 <0.001 <0.001 0.002 0.001
Eicosanoic acid (C20:0)0 . 0 1 <0.001 0.001 0.001 0.002
Gondoic acid (C20:1,n−9)0 . 0 2 <0.001 <0.001 0.004 0.002
Eicosadienoic acid 0.003 <0.001 <0.001 0.001 <0.001
(C20:2,n−6)
Dihomo-γ-linolenic acid <0.003 <0.001 <0.001 <0.001 <0.001
(C20:3,n−6)
Eicosatrienoic acid <0.003 0.001 0.001 0.008 0.001
(C20:3,n−3)
Arachidonic acid (C20:4,n−6) <0.003 <0.001 <0.001 0.001 <0.001
Eicosatetraenoic acid <0.003 <0.001 <0.001 0.001 <0.001
(C20:4,n−3)
Timnodonic acid (C20:5,n−3) <0.003 <0.001 <0.001 0.002 0.001
Behenic acid (C22:0)0 . 0 1 <0.001 <0.001 0.01 0.007
Cetoleic acid (C22:1,n−11) 0.003 <0.001 <0.001 0.023 0.002
Erucic acid (C22:1,n−9) 0.003 <0.001 <0.001 0.024 <0.001
Adrenic acid (C22:4,n−6) 0.003 0.001 0.001 0.004 0.001
Osbond acid (C22:5,n−6) 0.003 <0.001 <0.001 0.002 <0.001
Clupanodonic acid <0.003 <0.001 <0.001 0.003 <0.001
(C22:5,n−3)
Docosahexaenoic acid <0.003 <0.001 <0.001 0.012 <0.001
(C22:6,n−3)
Lignoceric acid (C24:0)0 . 0 1 <0.001 <0.001 0.005 0.002
Nervonic acid (C24:1,n−9) 0.003 <0.001 <0.001 0.007 <0.001
Unknown C4−10 acids <0.003 0.002 0.003 0.11 0.001
Unknown C10−15 acids <0.003 0.002 0.002 0.041 0.001
Unknown C15−20 acids 0.003 0.001 0.006 0.072 0.004
Unknown C20−25 acids 0.01 <0.001 0.001 0.157 0.003
1 To whom correspondence should be addressed (email c.r.wolf@dundee.ac.uk).
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Table S4 Fatty acid analysis of total hepatic lipids of control (Porlox/lox)
and HRN mice
Results are means+ −S.E.M. (n=3 livers). Fold change is expressed as the ratio of HRN mice
to control mice.
Fatty acid concentration (μM)
Fatty acid Control HRN P Fold change
Myristic acid (C14:0)1 . 3 + −0.2 3.5+ −1.4 0.202 2.7
Palmitic acid (C16:0) 24.5+ −1.0 86.7+ −2.9 <0.001 3.5
Palmitoleic acid (C16:1)2 . 5 + −0.01 17.1+ −3.8 0.019 6.8
Stearic acid (C18:0) 10.3+ −0.2 25.2+ −2.6 0.005 2.5
Oleic acid (C18:1) 15.2+ −0.5 213.3+ −18.1 <0.001 14.1
Linoleic acid (C18:2) 12.8+ −0.5 38.8+ −10.1 0.063 3.0
Eicosatrienoic acid (C20:3)1 . 2 + −0.1 7.5+ −0.4 <0.001 6.2
Arachidonic acid (C20:4) 10.1+ −0.6 18.3+ −1.1 0.003 1.8
Docosahexaenoic acid (C22:6)4 . 9 + −0.2 11.1+ −0.8 0.002 2.3
Table S5 Fatty acid analysis of total hepatic lipids of control (Porlox/lox)
and HRN mice
Results are means+ −S.E.M. (n=3 livers). Fold change is expressed as the ratio of HRN mice
to control mice.
Fatty acid concentration (μM)
Fatty acid group Control HRN P Fold change
Total 82.7+ −1.1 421.4+ −32.4 <0.001 5.1
C16:0/C18:0 ratio 2.4+ −0.1 3.5+ −0.3 0.024 1.5
Saturated 36.1+ −1.1 115.4+ −5.7 <0.001 3.2
Mono-unsaturated 17.7+ −0.5 230.4+ −20.8 <0.001 13.0
Polyunsaturated 28.9+ −0.6 75.7+ −11.9 0.018 2.6
n−34 . 9 + −0.2 11.1+ −0.8 0.002 2.3
n−6 24.1+ −0.5 64.6+ −11.2 0.022 2.7
Triacylglycerol (mM) 0.03+ −0.0004 0.14+ −0.01 <0.001 5.1
Table S6 The induction of other phenotypes in HRN mice on nuclear
receptor-null backgrounds
Pxr−/−/HRN, Car−/−/HRN and Pxr−/−/Car−/−/HRN mice were generated as outlined in the
Experimental section of the main text and were analysed at 12 weeks of age for non-fasting
plasma lipid concentrations and liver/body weight ratio as detailed in the Experimental section
of the main text. Results are means+ −S.E.M. (n = 3). *P 0.05; **P 0.01; ***P 0.001
compared with Porlox/lox (control) mice. †P 0.05 compared with HRN mice.
Genotype Plasma cholesterol Plasma triacylglycerols Liver/body weight ratio
Control (Porlox/lox)3 . 7 3 + −0.24 1.09+ −0.27 0.051+ −0.002
HRN 1.15+ −0.10*** 0.29+ −0.09* 0.075+ −0.004**
Pxr−/− 2.31+ −0.16* 0.41+ −0.13 0.062+ −0.001*
Car−/− 2.90+ −0.05 0.70+ −0.16 0.045+ −0.002
Pxr−/−/Car−/− 2.60+ −0.49 0.95+ −0.01 0.051+ −0.002
Pxr−/−/HRN 1.03+ −0.32** 0.14+ −0.01* 0.091+ −0.002***
Car−/−/HRN 1.35+ −0.15** 0.28+ −0.04* 0.073+ −0.007*
Pxr−/−/Car−/−/HRN 2.63+ −0.28† 0.61+ −0.12 0.073+ −0.004**
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Figure S1 Relationship of CYP2B10 and CYP3A11 expression with loss of POR activity and hepatic lipid accumulation
Porlox/lox/CreCYP1A1 and Porlox/lox mice were treated with a single dose of 3MC (40mg/kg of body weight), and harvested over a 28 day period. Hepatic triacylglycerol levels, mRNA
and protein levels of CYP2B10 and CYP3A11, and POR activity were determined as detailed in the Experimental section of the main text. (A) Relationship between POR activity and
(i) CYP2B10 protein, (ii) Cyp2b10 mRNA content. Correlation of Cyp2b10 mRNA with (iii) CYP2B10 protein and (iv) hepatic triacylglycerol (triglyceride) concentration. (B) Relationship
between POR activity and (i) CYP3A11 protein and (ii) Cyp3a11 mRNA content. Correlation of Cyp3a11 mRNA with (iii) CYP3A11 protein and (iv) hepatic triacylglycerol concentration. mRNA
expression and POR activity are expressed compared with 3MC-treated Porlox/lox mice. Results are means for three animals per experimental time point.
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Figure S2 Gene expression changes on loss of POR
Porlox/lox/CreCYP1A1 and Porlox/lox mice treated with a single dose of 3MC (40mg/kg of body
weight) were analysed for changes in the expression levels of various genes involved in
controlling hepatic lipid levels. mRNA expression of the fatty-acid transporter CD36 (A), FAS
(B), CPT1a (C) and CAR (D) as a function of time post 3MC administration. Results are
means+ −S.E.M. (n=3) and are expressed as a fold change compared with Porlox/lox mice at
the same time point. *P 0.05.
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Figure S3 Development of phenotypic changes in conditional HRN mice on
restricted fatty acid diets
Porlox/lox/CreCYP1A1 and Porlox/lox mice were maintained on a control, fat-deﬁcient or
fatty-acid-supplemented diet until 12 weeks of age as outlined in the Experimental section
of the main text, then treated with a single dose of 3MC (40mg/kg of body weight) and
killed14dayslater.Plasmalipidconcentrationsandliver/bodyweightratiosweredeterminedas
detailedintheExperimentalsectionofthemaintext.(A)Non-fastingtotalplasmacholesterol.(B)
Non-fasting plasma triacylglycerol (triglyceride) levels. (C) Liver/body weight ratio. Black bars:
Porlox/lox/CreCYP1A1. Grey bars: Porlox/lox. Results are means+ −S.E.M. (n=3). *P 0.05;
**P 0.01 compared with the same experimental conditions for Porlox/lox mice. aP 0.05;
bP 0.01comparedwithmiceofthesamegenotypeonacontroldiet.SFA,saturatedfattyacids;
MUFA, mono-unsaturated fatty acids; PUFA, polyunsaturated fatty acids; SunFl, 1% sunﬂower
oil.
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